Stammdaten
Arcutis Biotherapeutics, Inc., ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entwicklung und Vermarktung von Behandlungen für dermatologische Erkrankungen. Sein Lead-Produktkandidat ist ARQ-151, eine topische Roflumilast-Creme, die Phase-III-Kliniktests für die Behandlung von Plaquepsoriasis und atopischer Dermatitis abgeschlossen hat. Das Unternehmen entwickelt auch ARQ-154, eine topische Schaum-Formulierung von Roflumilast zur Behandlung von seborrhoischer Dermatitis und Kopfhaut-Psoriasis; ARQ-252, einen selektiven topischen Janus-Kinase-Typ-1-Inhibitor für Handekzem und Vitiligo; und ARQ-255, eine topische Formulierung von ARQ-252, die dazu bestimmt ist, tiefer in die Haut vorzudringen, um Alopecia areata (kreisrunden Haarausfall) zu behandeln. Das Unternehmen hieß früher Arcutis, Inc. und änderte seinen Namen im Oktober 2019 in Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics, Inc. wurde 2016 gegründet und hat seinen Sitz in Westlake Village, Kalifornien. KI
Unternehmen & Branche
| Name | Arcutis Biotherapeutics, Inc. |
|---|---|
| Ticker | ARQT |
| CIK | 0001787306 |
| Börse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 03969K108 |
|---|---|
| ISIN | US03969K1088 |
| Typ | Common Stock |
| Marktkapitalisierung | 3,42 Mrd. USD |
| Beta | 1,53 |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 3027 TOWNSGATE ROAD SUITE 300, 91361 WESTLAKE VILLAGE, CA |
| Telefon | 805-418-5006 |
| EIN (IRS) | 81-2974255 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | Arcutis, Inc. (bis 2019) |
Bewertung
| KBV (P/B) | 18,06 vs. 3,50 (2021) ▲ |
|---|---|
| KUV (P/S) | 9,10 |
| FCF-Rendite | -0,2 % vs. -16,8 % (2021) ▲ |
Qualität & Bilanz
| Bruttomarge | 90,2 % |
|---|---|
| Operative Marge | -3,3 % |
| Nettomarge | -4,3 % |
| ROIC | -5,3 % vs. -55,0 % (2021) ▲ |
| Zinsdeckungsgrad | -1,0 |
| Forderungslaufzeit (DSO) | 142 T |
| Lagerreichweite (DIO) | 225 T |
| Verbindlichkeitslaufzeit (DPO) | 125 T |
| Cash-Conversion-Cycle (CCC) | 242 T |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 3,50 | 4,31 | 3,53 | 10,42 | 18,90 | 18,04 | |
| KUV (P/S) | – | 245,08 | 5,24 | 8,35 | 9,52 | 8,23 | |
| FCF-Rendite | -16,8 % | -28,6 % | -79,2 % | -6,8 % | -0,2 % | 0,8 % | |
| Qualität & Bilanz | |||||||
| Bruttomarge | – | 79,5 % | 91,6 % | 90,3 % | 90,2 % | 90,9 % | |
| Operative Marge | – | -8.183,0 % | -404,5 % | -65,3 % | -3,3 % | 0,8 % | |
| Nettomarge | – | -8.449,8 % | -439,8 % | -71,3 % | -4,3 % | -0,6 % | |
| ROIC | -55,0 % | -75,6 % | -89,0 % | -52,2 % | -5,3 % | -0,8 % | |
| Zinsdeckungsgrad | – | -19,3 | -8,1 | -4,7 | -1,0 | 0,2 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
ARQT
Arcutis Biotherapeutics, Inc.
Effektiv
Neutral
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
36,1
35 neu, 99 erhöht, -786727K $ netto
Aktivist
12,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 24.04 | +18.5 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 24.93 | +14.3 % vs SMA200 | |
| SMA-Cross | Bärisch | 10 % | DEATH | vor 43 Tagen @ 21.57 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 26.81 | EMA50: 25.27 | |
| MACD-Histogramm | Bärisch | 10 % | -0.048 | Bearisch | |
| RSI(14) | Neutral | 10 % | 64.7 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 70.6 | Neutral | |
| ADX(14)+DI | Bullisch | 10 % | 36.6 | +DI: 31.8 / −DI: 15.1 | |
| Z-Score(60) | Bärisch | 5 % | 1.74 | Extrem überkauft | |
| 52W-Position | Bullisch | 5 % | 84.1 % | Hoch 31.20 / Tief 14.12 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 90.1 % | Upper 28.84 / Mid 27.08 / Lower 25.31 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.1145 | R²=0.56 / annualisiert +120.7 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-15 | Welgus Howard G. | Director | Open Market Sale | -4.730 | 26,91 | -127.284,30 | -64,1% | |
| 2026-06-17 | Welgus Howard G. | Director | Open Market Sale | -635 | 25,67 | -16.300,45 | -8,2% | |
| 2026-06-15 | LIN SUE-JEAN | Director | Open Market Sale | -4.946 | 24,38 | -120.586,94 | -60,8% | |
| 2026-06-15 | Welgus Howard G. | Director | Open Market Sale | -4.096 | 24,41 | -99.980,49 | -50,4% | |
| 2026-05-11 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -222 | 21,05 | -4.673,10 | -2,4% | |
| 2026-05-11 | Vairavan Latha | Officer, SVP Chief Financial Officer | Open Market Sale | -435 | 21,05 | -9.156,75 | -4,6% | |
| 2026-05-04 | Vairavan Latha | Officer, SVP Chief Financial Officer | Open Market Sale | -1.341 | 23,61 | -31.661,81 | -16,0% | |
| 2026-05-04 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -3.172 | 23,61 | -74.892,82 | -37,7% | |
| 2026-05-04 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -7.372 | 23,27 | -171.543,49 | -86,5% | |
| 2026-05-04 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -884 | 23,61 | -20.871,77 | -10,5% | |
| 2026-05-04 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -684 | 23,61 | -16.149,65 | -8,1% | |
| 2026-05-01 | Welgus Howard G. | Director | Open Market Sale | -7.144 | 22,99 | -164.219,84 | -82,8% | |
| 2026-04-01 | Welgus Howard G. | Director | Open Market Sale | -10.000 | 23,88 | -238.801,00 | -120,3% | |
| 2026-03-02 | Vairavan Latha | Officer, SVP Chief Financial Officer | Open Market Sale | -81 | 25,91 | -2.099,03 | -1,1% | |
| 2026-03-02 | Welgus Howard G. | Director | Open Market Sale | -10.000 | 25,65 | -256.518,00 | -129,3% | |
| 2026-03-02 | Leonard Keith R | Director | Open Market Sale | -39.272 | 25,39 | -997.194,62 | -502,5% | |
| 2026-03-02 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -6.553 | 25,16 | -164.876,10 | -83,1% | |
| 2026-03-02 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -1.987 | 25,70 | -51.065,90 | -25,7% | |
| 2026-03-02 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -193 | 25,91 | -5.001,38 | -2,5% | |
| 2026-03-02 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -36.281 | 25,16 | -912.851,73 | -460,0% | |
| 2026-03-02 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -1.068 | 25,91 | -27.676,05 | -13,9% | |
| 2026-03-02 | Edwards Larry Todd | Officer, See Remarks | Open Market Sale | -3.584 | 25,16 | -90.177,02 | -45,4% | |
| 2026-03-02 | Edwards Larry Todd | Officer, See Remarks | Open Market Sale | -103 | 25,91 | -2.669,23 | -1,3% | |
| 2026-03-02 | Vairavan Latha | Officer, SVP Chief Financial Officer | Open Market Sale | -2.772 | 25,16 | -69.744,91 | -35,1% | |
| 2026-03-02 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -6.106 | 25,16 | -153.629,40 | -77,4% | |
| 2026-03-02 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -181 | 25,91 | -4.690,43 | -2,4% | |
| 2026-02-27 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -3.325 | 27,95 | -92.933,75 | -46,8% | |
| 2026-02-04 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -9.794 | 25,81 | -252.747,88 | -127,4% | |
| 2026-02-02 | Welgus Howard G. | Director | Open Market Sale | -10.000 | 25,05 | -250.483,00 | -126,2% | |
| 2026-02-02 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -19.833 | 25,50 | -505.709,77 | -254,9% | |
| 2026-02-02 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -19.379 | 25,24 | -489.125,96 | -246,5% | |
| 2026-02-02 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -3.675 | 25,50 | -93.706,62 | -47,2% | |
| 2026-02-02 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -7.983 | 25,50 | -203.553,73 | -102,6% | |
| 2026-02-02 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -4.714 | 25,63 | -120.819,82 | -60,9% | |
| 2026-02-02 | Vairavan Latha | Officer, SVP Chief Financial Officer | Open Market Sale | -1.320 | 25,50 | -33.657,89 | -17,0% | |
| 2026-02-02 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -8.562 | 24,97 | -213.793,14 | -107,7% | |
| 2026-02-02 | Edwards Larry Todd | Officer, See Remarks | Open Market Sale | -2.052 | 25,50 | -52.322,72 | -26,4% | |
| 2026-01-05 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -2.490 | 28,98 | -72.165,68 | -36,4% | |
| 2026-01-02 | Welgus Howard G. | Director | Open Market Sale | -10.000 | 28,96 | -289.606,00 | -145,9% | |
| 2025-12-31 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -1.156 | 29,39 | -33.974,03 | -17,1% | |
| 2025-12-31 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -541 | 28,81 | -15.586,21 | -7,9% | |
| 2025-12-15 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -11.500 | 28,94 | -332.851,40 | -167,7% | |
| 2025-12-01 | Welgus Howard G. | Director | Open Market Sale | -10.000 | 30,21 | -302.133,00 | -152,3% | |
| 2025-12-01 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -1.657 | 30,23 | -50.091,11 | -25,2% | |
| 2025-11-24 | LIN SUE-JEAN | Director | Open Market Sale | -25.272 | 30,78 | -777.955,56 | -392,1% | |
| 2025-11-24 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -48.945 | 30,36 | -1.485.754,84 | -748,8% | |
| 2025-11-21 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -1.055 | 30,00 | -31.650,00 | -16,0% | |
| 2025-11-20 | Gilbert Halley E | Director | Open Market Sale | -16.532 | 27,55 | -455.441,72 | -229,5% | |
| 2025-11-19 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -1.561 | 28,50 | -44.488,50 | -22,4% | |
| 2025-11-19 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -989 | 27,95 | -27.646,60 | -13,9% | |
| 2025-11-13 | Krishnamohan Neha | Director | Open Market Sale | -39.272 | 23,19 | -910.701,97 | -459,0% | |
| 2025-11-13 | Krishnamohan Neha | Director | Open Market Sale | -1.232 | 23,37 | -28.791,84 | -14,5% | |
| 2025-11-06 | Edwards Larry Todd | Officer, See Remarks | Open Market Sale | -29.131 | 25,16 | -732.927,22 | -369,4% | |
| 2025-11-06 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -17.250 | 24,18 | -417.144,68 | -210,2% | |
| 2025-11-05 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -3.864 | 23,72 | -91.643,26 | -46,2% | |
| 2025-11-03 | Vairavan Latha | Officer, SVP Chief Financial Officer | Open Market Sale | -88 | 24,72 | -2.175,23 | -1,1% | |
| 2025-11-03 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -2.607 | 24,71 | -64.425,23 | -32,5% | |
| 2025-11-03 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -15 | 25,40 | -381,00 | -0,2% | |
| 2025-11-03 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -7.165 | 24,71 | -177.063,63 | -89,2% | |
| 2025-11-03 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -43 | 25,40 | -1.092,14 | -0,6% | |
| 2025-11-03 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -11.478 | 24,71 | -283.646,63 | -142,9% | |
| 2025-11-03 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -69 | 25,40 | -1.752,54 | -0,9% | |
| 2025-11-03 | Welgus Howard G. | Director | Open Market Sale | -10.000 | 25,27 | -252.669,00 | -127,3% | |
| 2025-10-28 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -40.000 | 25,03 | -1.001.032,00 | -504,5% | |
| 2025-10-02 | Edwards Larry Todd | Officer, See Remarks | Open Market Sale | -4.207 | 19,99 | -84.091,62 | -42,4% | |
| 2025-10-02 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -20.739 | 20,04 | -415.574,30 | -209,4% | |
| 2025-10-02 | Edwards Larry Todd | Officer, See Remarks | Open Market Sale | -297 | 20,78 | -6.171,69 | -3,1% | |
| 2025-10-01 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -9.261 | 20,02 | -185.371,88 | -93,4% | |
| 2025-10-01 | Welgus Howard G. | Director | Open Market Sale | -9.538 | 18,92 | -180.484,71 | -91,0% | |
| 2025-10-01 | Welgus Howard G. | Director | Open Market Sale | -462 | 18,92 | -8.742,29 | -4,4% | |
| 2025-10-01 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -15.000 | 18,91 | -283.702,50 | -143,0% | |
| 2025-09-09 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -504 | 17,52 | -8.829,02 | -4,4% | |
| 2025-09-08 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -9.625 | 17,54 | -168.799,40 | -85,1% | |
| 2025-09-04 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -36.130 | 16,16 | -583.716,28 | -294,2% | |
| 2025-09-02 | Welgus Howard G. | Director | Open Market Sale | -10.000 | 15,64 | -156.383,00 | -78,8% | |
| 2025-08-21 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -2.438 | 15,57 | -37.968,92 | -19,1% | |
| 2025-08-19 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -1.750 | 16,16 | -28.280,70 | -14,3% | |
| 2025-08-08 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -3.847 | 14,03 | -53.988,41 | -27,2% | |
| 2025-08-04 | Matsuda Masaru | Officer, See Remarks | Open Market Sale | -6.330 | 14,33 | -90.687,38 | -45,7% | |
| 2025-08-04 | Watanabe Todd | Director, Officer, See Remarks | Open Market Sale | -11.547 | 14,33 | -165.429,25 | -83,4% | |
| 2025-08-04 | Vairavan Latha | Officer, SVP Chief Financial Officer | Open Market Sale | -89 | 14,33 | -1.275,07 | -0,6% | |
| 2025-08-04 | Burnett Patrick | Officer, See Remarks | Open Market Sale | -2.622 | 14,33 | -37.564,35 | -18,9% | |
| 2025-08-01 | Welgus Howard G. | Director | Open Market Sale | -6.110 | 14,30 | -87.362,00 | -44,0% | |
| 2025-08-01 | Welgus Howard G. | Director | Open Market Sale | -3.890 | 14,30 | -55.620,00 | -28,0% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 1301 von typischerweise 8364 Fonds (16 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 12.327.000 | 0 | 12.327.000 | 290.424.120 | Neu | +100,0% | |
| Frazier Life Sciences Management, L.P. | 9.874.511 | 0 | 9.874.511 | 232.643.479 | Neu | +100,0% | |
| BlackRock, Inc. | 9.200.411 | 0 | 9.200.411 | 216.761.686 | Neu | +100,0% | |
| Rubric Capital Management LP | 8.271.577 | 0 | 8.271.577 | 194.878.354 | Neu | +100,0% | |
| STATE STREET CORP | 6.296.197 | 0 | 6.296.197 | 148.338.401 | Neu | +100,0% | |
| Polar Capital Holdings Plc | 5.666.940 | 0 | 5.666.940 | 133.513.106 | Neu | +100,0% | |
| JENNISON ASSOCIATES LLC | 4.980.770 | 0 | 4.980.770 | 117.346.943 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.871.536 | 0 | 4.871.536 | 114.773.388 | Neu | +100,0% | |
| GILDER GAGNON HOWE & CO LLC | 4.304.010 | 0 | 4.304.010 | 101.402.476 | Neu | +100,0% | |
| MORGAN STANLEY | 4.218.931 | 0 | 4.218.931 | 99.398.031 | Neu | +100,0% | |
| UBS Group AG | 3.329.224 | 0 | 3.329.224 | 78.436.518 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 3.045.306 | 0 | 3.045.306 | 71.759.223 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 2.496.222 | 0 | 2.496.222 | 58.810.990 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 2.431.778 | 0 | 2.431.778 | 57.292.689 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 2.297.943 | 0 | 2.297.943 | 54.139.548 | Neu | +100,0% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2.226.029 | 0 | 2.226.029 | 52.445.243 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 2.221.289 | 0 | 2.221.289 | 52.333.569 | Neu | +100,0% | |
| Janus Henderson Group Ltd. | 1.854.566 | 0 | 1.854.566 | 43.684.303 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 1.603.013 | 0 | 1.603.013 | 37.766.986 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 1.463.228 | 0 | 1.463.228 | 34.473.689 | Neu | +100,0% | |
| OBERWEIS ASSET MANAGEMENT INC/ | 1.365.941 | 0 | 1.365.941 | 32.181.570 | Neu | +100,0% | |
| Pivotal bioVenture Partners Investment Advisor LLC | 1.355.892 | 0 | 1.355.892 | 31.944.816 | Neu | +100,0% | |
| Ensign Peak Advisors, Inc | 1.244.387 | 0 | 1.244.387 | 29.317.758 | Neu | +100,0% | |
| Perpetual Ltd | 1.109.657 | 909.546 | 200.111 | 29.095.206 | Aufgestockt | +22,0% | |
| Squarepoint Ops LLC | 1.103.490 | 0 | 1.103.490 | 25.998.224 | Neu | +100,0% | |
| Candriam S.C.A. | 1.086.651 | 0 | 1.086.651 | 25.601.498 | Neu | +100,0% | |
| FEDERATED HERMES, INC. | 1.077.267 | 0 | 1.077.267 | 25.380.411 | Neu | +100,0% | |
| BAMCO INC /NY/ | 1.072.189 | 0 | 1.072.189 | 25.260.773 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.012.555 | 0 | 1.012.555 | 23.855.796 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 976.512 | 0 | 976.512 | 23.006.622 | Neu | +100,0% | |
| Nuveen, LLC | 902.134 | 0 | 902.134 | 21.254.278 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 812.146 | 0 | 812.146 | 19.134.160 | Neu | +100,0% | |
| MPM BioImpact LLC | 733.966 | 0 | 733.966 | 17.292.239 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 724.067 | 0 | 724.067 | 17.059.019 | Neu | +100,0% | |
| Aberdeen Group plc | 645.066 | 0 | 645.066 | 15.197.755 | Neu | +100,0% | |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 636.200 | 0 | 636.200 | 14.988.872 | Neu | +100,0% | |
| Nearwater Capital Markets, Ltd | 607.300 | 0 | 607.300 | 14.307.988 | Neu | +100,0% | |
| Point72 Asset Management, L.P. | 590.877 | 0 | 590.877 | 13.921.062 | Neu | +100,0% | |
| Eversept Partners, LP | 576.580 | 0 | 576.580 | 13.584.225 | Neu | +100,0% | |
| FISHMAN JAY A LTD/MI | 566.730 | 0 | 566.730 | 13.352.159 | Neu | +100,0% | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 540.511 | 0 | 540.511 | 12.734.439 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 503.856 | 0 | 503.856 | 11.870.847 | Neu | +100,0% | |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | 500.000 | 0 | 500.000 | 11.780.000 | Neu | +100,0% | |
| M&G Plc | 469.082 | 0 | 469.082 | 11.257.968 | Neu | +100,0% | |
| AQR CAPITAL MANAGEMENT LLC | 468.253 | 0 | 468.253 | 11.032.040 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 460.323 | 0 | 460.323 | 10.845.210 | Neu | +100,0% | |
| Cormorant Asset Management, LP | 450.000 | 0 | 450.000 | 10.602.000 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 440.999 | 0 | 440.999 | 10.389.936 | Neu | +100,0% | |
| STEMPOINT CAPITAL LP | 413.792 | 0 | 413.792 | 9.748.940 | Neu | +100,0% | |
| Patient Square Capital LP | 400.645 | 0 | 400.645 | 9.439.196 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 1301 von typischerweise 8364 Fonds (16 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Perpetual Ltd | 1.109.657 | 909.546 | +22,0% | 29.095.206 | 72,87 | 100 % | 6 Q |
| PEREGRINE CAPITAL MANAGEMENT LLC | 291.447 | 306.272 | -4,8% | 7.641.740 | 19,14 | 37 % | 2 Q |
| Y-Intercept (Hong Kong) Ltd | 75.572 | 0 | +100,0% | 1.981.498 | 4,96 | 100 % | 4 Q |
| PSP Research LLC | 19.700 | 19.700 | 0,0% | 516.534 | 1,29 | 0 % | 3 Q |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 12.678 | 15.352 | -17,4% | 351.675 | 0,88 | 4 % | 8 Q |
| Ballentine Partners, LLC | 10.230 | 10.584 | -3,3% | 268.231 | 0,67 | 0 % | 6 Q |
| GAMMA Investing LLC | 1.014 | 1.095 | -7,4% | 26.587 | 0,07 | 100 % | 11 Q |
| Farther Finance Advisors, LLC | 746 | 352 | +111,9% | 19.660 | 0,05 | 0 % | 11 Q |
| 1620 INVESTMENT ADVISORS, INC. | 711 | 875 | -18,7% | 18.642 | 0,05 | 50 % | 2 Q |
| True Wealth Design, LLC | 80 | 80 | 0,0% | 2.098 | 0,01 | 0 % | 6 Q |
| Versant Capital Management, Inc | 80 | 80 | 0,0% | 2.098 | 0,01 | 100 % | 8 Q |
| Handelsbanken Fonder AB | 43.800 | 41.300 | +6,1% | 1.148 | 0,00 | 0 % | 3 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 12 | 1,6 | 40 |
| 31.03.2026 | ✓ | 266 | 139,5 | 3.246 |
| 31.12.2025 | ✓ | 278 | 136,1 | 3.857 |
| 30.09.2025 | ✓ | 238 | 131,4 | 2.440 |
| 30.06.2025 | ✓ | 225 | 128,1 | 1.751 |
| 31.03.2025 | ✓ | 236 | 130,0 | 2.360 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| M&G Plc | 469.082 | 11.257.968 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 366.000 | 8.622.960 |
| Penn Capital Management Company, LLC | 333.130 | 7.864.517 |
| PEREGRINE CAPITAL MANAGEMENT LLC | 306.272 | 7.215.768 |
| PRINCIPAL FINANCIAL GROUP INC | 168.826 | 3.977.541 |
| Tejara Capital Ltd | 166.191 | 3.915.460 |
| 1492 Capital Management LLC | 118.156 | 2.783.755 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 98.847 | 2.329.000 |
| Campbell & CO Investment Adviser LLC | 31.544 | 743.177 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 26.000 | 612.560 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| MARSHALL WACE, LLP | 2.431.778 | 1.977.545 | +435.4 % | 57.292.689 |
| STATE STREET CORP | 6.296.197 | 807.896 | +14.7 % | 148.338.401 |
| Squarepoint Ops LLC | 1.103.490 | 647.614 | +142.1 % | 25.998.224 |
| BAMCO INC /NY/ | 1.072.189 | 567.489 | +112.4 % | 25.260.773 |
| OBERWEIS ASSET MANAGEMENT INC/ | 1.365.941 | 557.541 | +69.0 % | 32.181.570 |
| BANK OF AMERICA CORP /DE/ | 2.221.289 | 547.835 | +32.7 % | 52.333.569 |
| FRANKLIN RESOURCES INC | 2.297.943 | 397.859 | +20.9 % | 54.139.548 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 503.856 | 377.877 | +300.0 % | 11.870.847 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 12.327.000 | 363.000 | +3.0 % | 290.424.120 |
| GEODE CAPITAL MANAGEMENT, LLC | 3.045.306 | 291.999 | +10.6 % | 71.759.223 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | 4.980.770 | -1.777.236 | -26.3 % | 117.346.943 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 448.207 | -718.141 | -61.6 % | 10.560 |
| Ensign Peak Advisors, Inc | 1.244.387 | -658.003 | -34.6 % | 29.317.758 |
| DEUTSCHE BANK AG\ | 389.847 | -540.355 | -58.1 % | 9.184.796 |
| Nuveen, LLC | 902.134 | -480.026 | -34.7 % | 21.254.278 |
| Jump Financial, LLC | 49.567 | -381.335 | -88.5 % | 1.167.799 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 540.511 | -373.509 | -40.9 % | 12.734.439 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2.226.029 | -336.416 | -13.1 % | 52.445.243 |
| BARCLAYS PLC | 28.965 | -302.613 | -91.3 % | 682.416 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 636.200 | -263.800 | -29.3 % | 14.988.872 |
Zusätzlich aktuell von 141 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck | Δ-Balken |
|---|---|---|---|---|---|---|---|
| 12.05.2026 | STATE STREET CORPORATION | Passiv (13G) | 5,10 % | 6.296.197 | Neu | – | |
| 08.05.2026 | PRUDENTIAL FINANCIAL INC | Passiv (13G/A) | 4,30 % | 5.302.713 | -1,40 pp | – | |
| 06.05.2026 | Jennison Associates LLC | Passiv (13G/A) | 4,00 % | 4.980.770 | -1,50 pp | – | |
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -5,19 pp | – | |
| 13.02.2026 | PRUDENTIAL FINANCIAL INC | Passiv (13G/A) | 5,70 % | 7.079.926 | -4,40 pp | – | |
| 13.02.2026 | Rubric Capital Management LP (+1) | Passiv (13G/A) | 6,75 % | 8.271.577 | -0,29 pp | – | |
| 30.01.2026 | Jennison Associates LLC | Passiv (13G/A) | 5,50 % | 6.758.006 | -4,70 pp | – | |
| 06.10.2025 | Jennison Associates LLC | Passiv (13G/A) | 10,20 % | 12.254.119 | +0,60 pp | – | |
| 20.08.2025 | James N. Topper | Aktivist (13D/A) | 7,40 % | 8.843.386 | -7,10 pp | FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII each a… | |
| 20.08.2025 | Frazier Life Sciences VIII, L.P. | Aktivist (13D/A) | 7,30 % | 8.785.284 | -7,20 pp | FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII each a… | |
| 20.08.2025 | Frazier Life Sciences XII, L.P. (+2) | Aktivist (13D/A) | 0,10 % | 127.549 | Neu | FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII each a… | |
| 20.08.2025 | Frazier Life Sciences XI, L.P. (+2) | Aktivist (13D/A) | 0,10 % | 73.087 | Neu | FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII each a… | |
| 20.08.2025 | Patrick J. Heron | Aktivist (13D/A) | 7,50 % | 8.943.712 | -7,10 pp | FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII each a… | |
| 20.08.2025 | FHM LIFE SCIENCES VIII, L.L.C. | Aktivist (13D/A) | 7,40 % | 8.785.291 | Neu | FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII each a… | |
| 20.08.2025 | Frazier Life Sciences Public Overage Fund, L.P. (+2) | Aktivist (13D/A) | 0,20 % | 196.170 | Neu | FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII each a… | |
| 20.08.2025 | Frazier Life Sciences Public Fund, L.P. (+2) | Aktivist (13D/A) | 0,60 % | 664.973 | Neu | FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII each a… | |
| 20.08.2025 | FHM LIFE SCIENCES VIII, L.P. | Aktivist (13D/A) | 7,40 % | 8.785.284 | Neu | FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII each a… | |
| 20.08.2025 | Frazier Life Sciences X, L.P. (+2) | Aktivist (13D/A) | 0,00 % | 27.448 | Neu | FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII each a… | |
| 14.08.2025 | Polar Capital Funds PLC - Biotechnology Fund (+2) | Passiv (13G/A) | 4,20 % | 5.006.472 | -0,86 pp | – | |
| 15.05.2025 | Polar Capital Funds PLC - Biotechnology Fund | Passiv (13G/A) | 5,06 % | 6.000.000 | -0,77 pp | – | |
| 15.05.2025 | Polar Capital Holdings Plc (+1) | Passiv (13G/A) | 5,65 % | 6.706.475 | -1,02 pp | – | |
| 15.05.2025 | PRUDENTIAL FINANCIAL INC | Passiv (13G/A) | 10,10 % | 11.954.070 | Neu | – | |
| 08.05.2025 | Jennison Associates LLC | Passiv (13G/A) | 9,60 % | 11.360.875 | Neu | – | |
| 14.11.2024 | Cubist Systematic Strategies, LLC | Passiv (13G/A) | Ausstieg | 0 | -0,10 pp | – | |
| 14.11.2024 | Point72 Asset Management, L.P. (+2) | Passiv (13G/A) | 0,20 % | 247.055 | -4,90 pp | – | |
| 13.11.2024 | Rubric Capital Management (+1) | Passiv (13G/A) | 9,38 % | 10.966.672 | Neu | – | |
| 08.11.2024 | . BlackRock, Inc. | Passiv (13G/A) | 7,70 % | 9.029.624 | 0,00 pp | – | |
| 06.11.2024 | Morgan Stanley | Passiv (13G/A) | 3,40 % | 3.993.787 | -3,10 pp | – | |
| 22.10.2024 | . BlackRock, Inc. | Passiv (13G/A) | 7,70 % | 9.029.624 | +1,40 pp | – | |
| 06.03.2024 | FHM Life Sciences VIII, L.L.C. | Aktivist (13D/A) | 7,80 % | 8.785.291 | -1,50 pp | – | |
| 06.03.2024 | James N. Topper | Aktivist (13D/A) | 7,80 % | 8.815.938 | -1,50 pp | – | |
| 06.03.2024 | Frazier Life Sciences VIII, L.P. (+1) | Aktivist (13D/A) | 7,80 % | 8.785.284 | -1,50 pp | – | |
| 06.03.2024 | Patrick J. Heron | Aktivist (13D/A) | 7,80 % | 8.862.478 | -1,60 pp | – | |
| 06.03.2024 | : Jennison Associates LLC | Passiv (13G/A) | 10,80 % | 12.128.533 | +1,20 pp | – | |
| 13.02.2024 | Polar Capital Holdings Plc (+1) | Passiv (13G/A) | 6,67 % | 6.297.688 | -0,89 pp | – | |
| 13.02.2024 | Polar Capital Funds PLC - Biotechnology Fund | Passiv (13G/A) | 5,83 % | 5.500.000 | -0,84 pp | – | |
| 13.02.2024 | The Vanguard Group | Passiv (13G) | 5,19 % | 4.896.513 | Neu | – | |
| 13.02.2024 | Averill Master Fund, Ltd. | Passiv (13G/A) | 9,10 % | 8.680.258 | 0,00 pp | – | |
| 13.02.2024 | Suvretta Capital Management, LLC (+1) | Passiv (13G/A) | 9,99 % | 9.534.837 | 0,00 pp | – | |
| 12.02.2024 | Rubric Capital Management LP (+1) | Passiv (13G) | 7,04 % | 6.644.530 | Neu | – |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 29.05.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 03.03.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 105.398.000 $ | -11.295.000 $ | -0,09 $ | 460.003.000 $ | 189.648.000 $ |
| 2025-12-31 | 10-K | 376.072.000 $ | -16.141.000 $ | -0,13 $ | 432.973.000 $ | 189.479.000 $ |
| 2025-09-30 | 10-Q | 99.219.000 $ | 7.410.000 $ | 0,06 $ | 370.977.000 $ | 158.073.000 $ |
| 2025-06-30 | 10-Q | 81.504.000 $ | -15.886.000 $ | -0,13 $ | 352.433.000 $ | 138.974.000 $ |
| 2025-03-31 | 10-Q | 65.846.000 $ | -25.060.000 $ | -0,20 $ | 344.105.000 $ | 142.658.000 $ |
| 2024-12-31 | 10-K | 196.542.000 $ | -140.039.000 $ | -1,16 $ | 348.889.000 $ | 157.541.000 $ |
| 2024-09-30 | 10-Q | 44.755.000 $ | -41.537.000 $ | -0,33 $ | 437.354.000 $ | 156.641.000 $ |
| 2024-06-30 | 10-Q | 30.858.000 $ | -52.332.000 $ | -0,42 $ | 444.759.000 $ | 186.427.000 $ |
| 2024-03-31 | 10-Q | 49.569.000 $ | -35.382.000 $ | -0,32 $ | 478.541.000 $ | 224.942.000 $ |
| 2023-12-31 | 10-K | 59.606.000 $ | -262.140.000 $ | -3,78 $ | 341.365.000 $ | 88.667.000 $ |
| 2023-09-30 | 10-Q | 38.109.000 $ | -44.765.000 $ | -0,73 $ | 292.959.000 $ | 46.717.000 $ |
| 2023-06-30 | 10-Q | 5.190.000 $ | -70.991.000 $ | -1,16 $ | 320.689.000 $ | 80.508.000 $ |
| 2023-03-31 | 10-Q | 2.781.000 $ | -80.100.000 $ | -1,31 $ | 379.458.000 $ | 139.732.000 $ |
| 2022-12-31 | 10-K | 3.686.000 $ | -311.458.000 $ | -5,66 $ | 449.274.000 $ | 209.581.000 $ |
| 2022-09-30 | 10-Q | – | -107.709.000 $ | -1,89 $ | 508.914.000 $ | 270.774.000 $ |
| 2022-06-30 | 10-Q | 0 $ | -67.406.000 $ | -1,31 $ | 300.464.000 $ | 195.382.000 $ |
| 2022-03-31 | 10-Q | – | -64.324.000 $ | -1,27 $ | 364.109.000 $ | 253.772.000 $ |
| 2021-12-31 | 10-K | – | -206.356.000 $ | -4,18 $ | 408.152.000 $ | 297.677.000 $ |
| 2021-09-30 | 10-Q | – | -56.980.000 $ | -1,14 $ | 387.008.000 $ | 362.995.000 $ |
| 2021-06-30 | 10-Q | – | -42.008.000 $ | -0,84 $ | 432.892.000 $ | 414.488.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|
| ZORYVEFoam | 181,9 Mio. | 71,5 Mio. | – | – | 48,9 % | +154,3% | |
| ZORYVECream 0.3 | 121,0 Mio. | 85,1 Mio. | – | – | 32,5 % | +42,2% | |
| ZORYVECream 0.15 | 68,3 Mio. | 9,9 Mio. | – | – | 18,3 % | +588,2% | |
| ZORYVECream 0.05 | 911.000 | – | – | – | 0,2 % | Neu | |
| Other Revenue | – | – | 30,4 Mio. | – | – | – | |
| Product | – | – | 29,2 Mio. | 3,7 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 06.05.2026 | 105,4 Mio. USD | -0,09 |
| Q3 2025 | 30.09.2025 | 28.10.2025 | 99,2 Mio. USD | 0,06 |
| Q2 2025 | 30.06.2025 | 06.08.2025 | 81,5 Mio. USD | -0,13 |
| Q1 2025 | 31.03.2025 | 06.05.2025 | 65,8 Mio. USD | -0,20 |
| Q3 2024 | 30.09.2024 | 06.11.2024 | 44,8 Mio. USD | -0,33 |
| Q2 2024 | 30.06.2024 | 14.08.2024 | 30,9 Mio. USD | -0,42 |
| Q1 2024 | 31.03.2024 | 14.05.2024 | 49,6 Mio. USD | -0,32 |
| Q3 2023 | 30.09.2023 | 03.11.2023 | 38,1 Mio. USD | -0,73 |
| Q2 2023 | 30.06.2023 | 08.08.2023 | 5,2 Mio. USD | -1,16 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 06.05.2026 | 10-Q | 31.03.2026 | 36 Tage | SEC » |
| 25.02.2026 | 10-K | 31.12.2025 | 56 Tage | SEC » |
| 28.10.2025 | 10-Q | 30.09.2025 | 28 Tage | SEC » |
| 06.08.2025 | 10-Q | 30.06.2025 | 37 Tage | SEC » |
| 06.05.2025 | 10-Q | 31.03.2025 | 36 Tage | SEC » |
| 25.02.2025 | 10-K | 31.12.2024 | 56 Tage | SEC » |
| 06.11.2024 | 10-Q | 30.09.2024 | 37 Tage | SEC » |
| 14.08.2024 | 10-Q | 30.06.2024 | 45 Tage | SEC » |
| 24.07.2024 | 10-Q/A | 31.03.2024 | 115 Tage | SEC » |
| 14.05.2024 | 10-Q | 31.03.2024 | 44 Tage | SEC » |
| 27.02.2024 | 10-K | 31.12.2023 | 58 Tage | SEC » |
| 03.11.2023 | 10-Q | 30.09.2023 | 34 Tage | SEC » |
| 15.09.2023 | 10-K/A | 31.12.2022 | 258 Tage | SEC » |
| 15.09.2023 | 10-Q/A | 30.06.2023 | 77 Tage | SEC » |
| 15.09.2023 | 10-Q/A | 31.03.2023 | 168 Tage | SEC » |
| 08.08.2023 | 10-Q | 30.06.2023 | 39 Tage | SEC » |
| 09.05.2023 | 10-Q | 31.03.2023 | 39 Tage | SEC » |
| 28.02.2023 | 10-K | 31.12.2022 | 59 Tage | SEC » |
| 08.11.2022 | 10-Q | 30.09.2022 | 39 Tage | SEC » |
| 04.08.2022 | 10-Q | 30.06.2022 | 35 Tage | SEC » |
| 05.05.2022 | 10-Q | 31.03.2022 | 35 Tage | SEC » |
| 03.03.2022 | 10-K/A | 31.12.2021 | 62 Tage | SEC » |
| 22.02.2022 | 10-K | 31.12.2021 | 53 Tage | SEC » |
| 04.11.2021 | 10-Q | 30.09.2021 | 35 Tage | SEC » |
| 05.08.2021 | 10-Q | 30.06.2021 | 36 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 16.02.2021 | 10-K | 31.12.2020 | 47 Tage | SEC » |
| 05.11.2020 | 10-Q | 30.09.2020 | 36 Tage | SEC » |
| 11.08.2020 | 10-Q | 30.06.2020 | 42 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 01.03.2024 | Kapitalerhöhung | $15,0 Mio · $9,50/Aktie | SEC » |
| 28.02.2024 | Kapitalerhöhung | $150,0 Mio | SEC » |
| 08.02.2024 | Kapitalerhöhung | $100,0 Mio | SEC » |
| 23.10.2023 | Kapitalerhöhung | $100,0 Mio · $2,50/Aktie | SEC » |
| 19.10.2023 | Kapitalerhöhung | $100,0 Mio | SEC » |
| 04.08.2022 | Kapitalerhöhung | $150,0 Mio · $20,00/Aktie | SEC » |
| 02.08.2022 | Kapitalerhöhung | $150,0 Mio | SEC » |
| 06.05.2021 | Kapitalerhöhung | $100,0 Mio | SEC » |
| 04.02.2021 | Kapitalerhöhung | $181,0 Mio · $35,00/Aktie | SEC » |
| 01.02.2021 | Kapitalerhöhung | $148,3 Mio · $27,29/Aktie | SEC » |
| 05.10.2020 | Börsengang | $100,0 Mio · $25,00/Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 21.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 21.04.2026 | HV-Einladung | 05.06.2026 Jahres-HV | 08.04.2026 | DEF 14A | SEC » |
| 29.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 29.04.2025 | HV-Einladung | 12.06.2025 Jahres-HV | 15.04.2025 | DEF 14A | SEC » |
| 26.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 26.04.2024 | HV-Einladung | 14.06.2024 Jahres-HV | 22.04.2024 | DEF 14A | SEC » |
| 18.04.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 18.04.2023 | HV-Einladung | 31.05.2023 Jahres-HV | 03.04.2023 | DEF 14A | SEC » |
| 19.04.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 19.04.2022 | HV-Einladung | 01.06.2022 Jahres-HV | 04.04.2022 | DEF 14A | SEC » |
| 27.04.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 27.04.2021 | HV-Einladung | 09.06.2021 Jahres-HV | 13.04.2021 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Übernahmen & Fusionen (M&A)
M&A-relevante SEC-Filings der letzten sechs Jahre: Übernahmeangebote (Tender Offers), Fusionen (425/S-4), Aktienrückkauf-Angebote (Self-Tender) und Going-Private-Transaktionen. Geführt nach dem einreichenden Emittenten.
| Datum (US) | Kategorie | Form | Deal-Konditionen | SEC |
|---|---|---|---|---|
| 15.02.2024 | Aktienrückkauf | SC TO-I/A | – | SEC » |
| 24.01.2024 | Aktienrückkauf | SC TO-I/A | – | SEC » |
| 16.01.2024 | Aktienrückkauf | SC TO-I | Frist 12.02.2024 | SEC » |
| 11.01.2024 | Übernahmeangebot | SC TO-C | – | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Deal-Konditionen aus dem Dokument extrahiert (Tender: SC TO-T/-I/SC 14D9; Fusion: 425/S-4 — Gegenpartei + Umtauschverhältnis), ohne Gewähr — Original siehe SEC-Link.
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (16.07.2026)
HOCH Abgang Schlüsselpersonen (16.07.2026)
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 16.07.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 08.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 10.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 15.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 27.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 07.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 24.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 29.07.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 16.07.2026 | Personalwechsel | 0,20 | 35 | Arcutis Biotherapeutics, Inc. hat Christopher Peetz als neues Mitglied des Vorstands ernannt. Er bringt umfangreiche Erfahrung in der Biotec… 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-29 | 361 | 27,00 | 9.747 |
| 2026-06-24 | 2.607 | 26,27 | 68.486 |
| 2026-06-15 | 55 | 24,38 | 1.341 |
| 2026-06-11 | 797 | 23,23 | 18.514 |
| 2026-06-09 | 420 | 21,54 | 9.047 |
| 2026-06-08 | 465 | 21,23 | 9.872 |
| 2026-06-05 | 1.902 | 21,95 | 41.749 |
| 2026-06-03 | 125 | 20,79 | 2.599 |
| 2026-06-01 | 9 | 21,46 | 193 |
| 2026-05-14 | 1.982 | 21,69 | 42.990 |
| 2026-05-13 | 14.724 | 20,69 | 304.640 |
| 2026-04-30 | 57 | 22,37 | 1.275 |
| 2026-04-21 | 4.150 | 24,47 | 101.551 |
| 2026-04-20 | 175 | 24,53 | 4.293 |
| 2026-04-14 | 462 | 24,12 | 11.143 |
| 2026-03-30 | 990 | 21,22 | 21.008 |
| 2026-03-18 | 1.449 | 22,72 | 32.921 |
| 2026-03-17 | 41 | 22,76 | 933 |
| 2026-03-06 | 1 | 23,97 | 24 |
| 2026-02-26 | 6 | 27,01 | 162 |
| 2026-02-25 | 7 | 26,98 | 189 |
| 2026-02-24 | 1 | 26,31 | 26 |
| 2026-01-21 | 21.771 | 25,87 | 563.216 |